 "Jubilant Life Sciences")
Jubilant Life Sciences today posted a consolidated net loss of Rs 94.11 crore for the second quarter ended September 30, 2014.
The company had posted a net loss of Rs 80.58 crore during the same period of previous fiscal.
Its net sales in the quarter under review stood at Rs 1,362.11 crore during the period, down 4.36% compared to Rs 1,424.3 crore in the same period previous fiscal, Jubilant Life Sciences said in a BSE filing.
Jubilant Life Sciences, Chairman and Managing Director, Shyam S Bhartia said: "The company's performance in the quarter was affected mainly due to the continued impact of US FDA Warning letter on Spokane facility and adverse price impact on account of new capacities and regulatory changes in China in Advanced Intermediates business."
Overall expenses of the company went up by 7.56% to Rs 1,329.29 crore in Q2 of FY'15 against Rs 1,235.75 crore in the Q2 of FY'14.
During the quarter under review, revenue of pharmaceuticals segment declined 11.34% to Rs 614.30 crore, while revenue from life science ingredients segment went up by 1.67% to Rs 756.8 crore.
For the half year ended September 30, the company posted a net loss of Rs 89.33 crore as against net loss of Rs 133.20 crore in the year ago period.
Net sales of the company for the half year ended September 30, rose to Rs 2,822.64 crore compared to Rs 2,742.34 crore in same period previous fiscal.
Shares of Jubilant Life Sciences closed at Rs 165.80 apiece, up 1.72% from their previous close on BSE.
